Prioritizing the Pathogens: Decoding the WHO Bacterial Priority Pathogens List vs. CDC Antibiotic Resistance Threats

Abstract

This article provides a comparative analysis for researchers and drug development professionals of the two foremost global frameworks for prioritizing antibiotic-resistant bacteria: the WHO Bacterial Priority Pathogens List (BPPL) and the CDC's Antibiotic Resistance Threats Report. We examine their foundational methodologies, distinct purposes in guiding R&D investment and public health action, practical application in trial design and surveillance, and the critical points of alignment and divergence. The synthesis offers strategic insights for optimizing antimicrobial development pipelines and strengthening global coordination against antimicrobial resistance (AMR).

Blueprint vs. Snapshot: Understanding the Core Mandates of WHO BPPL and CDC Threats List

Comparison Guide: WHO BPPL vs. CDC Antibiotic Resistance Threats List in Guiding R&D

This guide objectively compares the Bacterial Priority Pathogens List (BPPL) from the World Health Organization (WHO) and the Antibiotic Resistance Threats List from the U.S. Centers for Disease Control and Prevention (CDC) as frameworks for directing global public health research and development.

Table 1: Core Governance and Mandate Comparison

Feature	WHO Bacterial Priority Pathogens List (BPPL)	CDC Antibiotic Resistance Threats List
Primary Mandate	Global public health R&D prioritization to guide discovery of new antibiotics.	U.S. public health protection, guiding domestic prevention and response.
Geographic Scope	Global; intended for all WHO Member States.	Primarily United States; used domestically with global implications.
Latest Update	2024 (BPPL).	2019 (AR Threats Report); 2022 (COVID-19 Special Edition).
Pathogen Categorization	Critical, High, Medium priority based on R&D urgency.	Urgent, Serious, Concerning threats based on domestic impact.
Key Metrics for Ranking	Drug-resistant burden, transmissibility, treatability, prevention potential, R&D pipeline status.	Number of infections, deaths, treatability, transmissibility, available prevention tools.
Primary Target Audience	Researchers, pharmaceutical developers, public health agencies globally.	U.S. healthcare providers, policymakers, public health departments.

Table 2: Alignment of Priority Pathogens (2024/2019 Data)

Pathogen/Drug-Resistance Profile	WHO BPPL (2024) Priority Category	CDC Threats List (2019) Threat Category
Carbapenem-resistant Acinetobacter baumannii	Critical	Urgent
Carbapenem-resistant Pseudomonas aeruginosa	Critical	Serious
Third-generation cephalosporin-resistant & Carbapenem-resistant Enterobacterales	Critical	Urgent (C. auris: Urgent)
Methicillin-resistant Staphylococcus aureus (MRSA)	High	Serious
Vancomycin-resistant Enterococcus faecium (VRE)	High	Serious
Fluconazole-resistant Candida albicans	High	Concerning

Experimental Protocol for Evaluating Pathogen Priority Methodologies

Title: Comparative Analysis of Pathogen Ranking Frameworks

Objective: To quantitatively compare the outcomes and influencing variables of the WHO BPPL and CDC AR Threats List prioritization methodologies.

Methodology:

• Data Acquisition: Compile the full list of pathogens and associated metadata (e.g., incidence, mortality, treatment options, R&D pipeline data) from the 2024 WHO BPPL report and the 2019 CDC AR Threats Report.
• Variable Normalization: Standardize all quantitative metrics (e.g., disability-adjusted life years (DALYs) for WHO, estimated infections for CDC) into a common scale (0-1) for comparison where possible.
• Weight Assignment Simulation: Model the implicit weighting of criteria (e.g., treatability vs. transmissibility) used by each agency by applying multi-criteria decision analysis (MCDA).
• Outcome Correlation Analysis: Calculate the Spearman's rank correlation coefficient between the final priority rankings of pathogens common to both lists.
• Sensitivity Analysis: Test how changes in input variables (e.g., a 20% increase in global mortality estimates) affect the final ranking in each model.

Expected Data Output: A correlation coefficient (ρ) indicating the degree of alignment between the two lists, and identification of the criteria (e.g., "R&D pipeline gap" vs. "domestic incidence") that cause the most significant divergence in rankings.

Title: Workflow for Comparing Pathogen Ranking Methodologies

Title: Decision Logic for Pathogen Prioritization

The Scientist's Toolkit: Key Research Reagent Solutions for AMR R&D

Table 3: Essential Materials for Antimicrobial Resistance (AMR) Research

Item	Function in AMR R&D
Reference Strain Panels (e.g., WHO Global Priority Pathogen isolates, CDC & FDA AR Isolate Bank strains)	Provide standardized, characterized bacterial/fungal strains with defined resistance mechanisms for assay validation and comparative studies.
CRISPR-Cas9 Gene Editing Systems	Enable precise knock-out/in of resistance genes to study their function and validate novel drug targets.
Chemical Libraries & Fragment-Based Screening Collections	Contain thousands of diverse compounds for high-throughput screening against priority pathogens to identify novel lead molecules.
In Vitro Pharmacokinetic/Pharmacodynamic (PK/PD) Models (e.g., hollow-fiber, chemostat systems)	Simulate human drug concentration-time profiles in vitro to optimize dosing regimens for new antibiotics against resistant strains.
Whole Genome Sequencing (WGS) Kits & Bioinformatics Pipelines	Allow for rapid identification of resistance determinants, outbreak tracing, and understanding of resistance evolution.
Animal Infection Models (e.g., murine neutropenic thigh, lung infection models)	Provide in vivo data on efficacy and toxicity of novel antimicrobials in a complex biological system, critical for pre-clinical development.

This guide compares the CDC's Antibiotic Resistance (AR) Threats Report with the WHO Bacterial Priority Pathogens List (WHO BPPL), focusing on their application in surveillance systems and research & development prioritization.

Comparative Analysis: WHO BPPL vs. CDC AR Threats List

Primary Objectives & Scope

Feature	CDC AR Threats List	WHO Bacterial Priority Pathogens List (BPPL)
Primary Objective	Guide U.S. public health action, inform domestic policy, funding, and prevention programs.	Guide global R&D for new antibiotics, direct international research investment.
Geographic Scope	National (United States).	Global.
Core Focus	Burden of illness (infections, deaths, healthcare costs), transmission tracking, and actionable containment.	Assessment of global drug-resistant bacterial R&D needs based on prevalence, mortality, and treatment barriers.
Update Cycle	~5 years (2013, 2019, 2022 update).	Revised as needed (2017, 2024).
Categorization	Urgent, Serious, Concerning, Watch List.	Critical, High, Medium Priority.
Key Metric	Domestic incidence, mortality, and projected threat level.	Global antibiotic resistance burden, transmissibility, treatability, and R&D pipeline gaps.

Quantitative Comparison of 2022/2024 Listings

Pathogen/Antibiotic Combo	CDC AR Threats 2022	WHO BPPL 2024	Alignment
Carbapenem-resistant Acinetobacter	Urgent	Critical Priority	High
Carbapenem-resistant Enterobacterales	Urgent	Critical Priority	High
Candida auris	Urgent	Critical Priority (under fungi)	High
Drug-resistant Neisseria gonorrhoeae	Urgent	High Priority	Partial
Methicillin-resistant Staphylococcus aureus	Serious	High Priority	Partial
ESBL-producing Enterobacterales	Serious	High Priority	High
Clostridioides difficile	Urgent	Not Included (non-resistant pathogen)	None

Experimental Protocol for Comparative Burden Analysis

Title: Protocol for Cross-Referencing Pathogen Priority via Surveillance Data.

Objective: To empirically compare the CDC and WHO lists by analyzing the correlation between U.S. surveillance burden metrics and global R&D priority scores.

Methodology:

• Data Acquisition: Extract U.S. annual incidence and mortality data for each CDC-listed pathogen from the CDC's National Healthcare Safety Network (NHSN) and Emerging Infections Program (EIP) databases. In parallel, extract WHO BPPL priority scores (based on criteria: mortality, treatability, transmissibility, R&D pipeline).
• Normalization: Normalize CDC data to per-100,000 population rates. Normalize WHO scores on a 0-1 scale.
• Correlation Analysis: Perform a Spearman's rank correlation analysis between the CDC's domestic burden rank (Urgent=3, Serious=2, etc.) and the WHO's global priority rank (Critical=3, High=2, Medium=1).
• Discrepancy Identification: Identify pathogens where rank divergence is >2 positions. Conduct a qualitative review of policy documents to attribute divergence to scope differences (e.g., domestic outbreak vs. global R&D gap).

Logical Workflow for Public Health Action Based on Surveillance

Diagram Title: CDC Surveillance to Public Health Action Workflow

Comparative Framework for Guiding Research & Development

Diagram Title: WHO vs. CDC R&D Priority Pathways

The Scientist's Toolkit: Key Reagents & Materials for AR Surveillance Research

Research Reagent / Material	Primary Function	Example Application
PCR & Whole Genome Sequencing (WGS) Kits	Detect and characterize resistance genes (blaKPC, blaNDM, mcr-1).	Confirming carbapenem or colistin resistance mechanisms in Enterobacterales.
Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) Mass Spectrometry	Rapid, accurate microbial identification to species level.	Differentiating Candida auris from other Candida species in surveillance cultures.
Automated Antimicrobial Susceptibility Testing (AST) Systems	Generate Minimum Inhibitory Concentration (MIC) data for multiple drugs.	Determining if an Acinetobacter isolate is multi-drug or extensively-drug resistant per CDC/CLSI guidelines.
Selective & Chromogenic Media (e.g., CRE, MRSA screening agar)	Selective isolation of resistant pathogens from complex samples (stool, swabs).	Active surveillance for ESBL or CRE colonization in hospital admission screening.
Multilocus Sequence Typing (MLST) or cgMLST Reagents	High-resolution molecular typing for outbreak investigation.	Linking cases of carbapenem-resistant Pseudomonas aeruginosa to a specific hospital unit or device.

Within the critical field of antimicrobial resistance (AMR) research, the designation of a "Priority Pathogen" serves as a strategic tool to guide funding, drug discovery, and public health intervention. This guide objectively compares the two most influential global frameworks for pathogen prioritization: the World Health Organization (WHO) Bacterial Priority Pathogens List (BPPL) and the U.S. Centers for Disease Control and Prevention (CDC) Antibiotic Resistance Threats list. Understanding their comparative methodologies, taxonomies, and underlying data is essential for researchers and drug development professionals aligning their work with public health needs.

Comparative Framework: WHO BPPL vs. CDC Threats List

Foundational Criteria and Scoring Methodology

WHO BPPL: The 2024 WHO BPPL employs a multi-criteria decision analysis (MCDA) framework. Pathogens are evaluated and ranked based on a weighted composite score of 11 criteria across two domains: Global Public Health Impact (e.g., incidence, mortality, treatability, transmissibility) and Unmet R&D Needs (e.g., current pipeline, drug feasibility). Expert panels assign final priority tiers (Critical, High, Medium).

CDC Threats List: The 2019 CDC AR Threats Report categorizes pathogens into threat levels (Urgent, Serious, Concerning) based primarily on Domestic U.S. Impact. Key criteria include clinical and economic burden, incidence, 10-year projection of trends, transmissibility, and availability of effective antibiotics. It includes fungi (Candida auris) and incorporates a "Watch List."

Table 1: Core Prioritization Criteria Comparison

Criteria Category	WHO BPPL (2024)	CDC AR Threats (2019)
Primary Scope	Global public health & R&D needs	U.S. domestic health impact & burden
Key Metrics	Mortality, incidence, treatability, transmissibility, R&D pipeline	Estimated cases/deaths, healthcare costs, transmissibility, future projection
Pathogen Types	Bacteria (including Mycobacterium tuberculosis)	Bacteria, Fungi (C. auris)
Priority Tiers	Critical, High, Medium	Urgent, Serious, Concerning, Watch List
Data Integration	Systematic reviews, global surveillance (GLASS, etc.), expert consensus	U.S. national/regional surveillance (NHSN, NAMSS), burden modeling (CDC Epicenter)
R&D Focus	Explicit, direct weighting in scoring	Implicit, considered within "available antibiotics" criterion

Experimental Protocol for Burden Estimation (Common to Both Lists):

• Objective: To quantify the annual morbidity, mortality, and economic burden attributable to antibiotic-resistant infections.
• Data Sources: (A) National laboratory-based surveillance networks for incidence and resistance rates. (B) Hospital discharge databases. (C) Vital statistics (mortality records). (D) Published cohort studies for attributable mortality and length-of-stay.
• Methodology:
  • Case Estimation: Multiply healthcare utilization data by resistance proportions from surveillance.
  • Attributable Burden: Use meta-analyses or matched cohort studies to calculate the increased risk of death or prolonged hospitalization due to resistance.
  • Modeling: Utilize statistical models (e.g., population-based simulation, regression) to extrapolate to the national (CDC) or global (WHO) population, accounting for under-reporting.
  • Economic Costing: Apply cost-per-day and productivity loss estimates to attributable hospital days and deaths.

Taxonomic Alignment and Discrepancies

A direct comparison reveals significant overlap in pathogens deemed "Critical"/"Urgent" (e.g., carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacterales), highlighting a global consensus on the most severe threats.

Table 2: Pathogen Ranking Comparison (Top Tiers)

Pathogen / Resistance Profile	WHO BPPL 2024 Tier	CDC Threats 2019 Level	Key Discrepancy Note
Carbapenem-resistant A. baumannii	Critical	Urgent	Strong alignment.
Carbapenem-resistant P. aeruginosa	Critical	Serious	WHO ranks higher, emphasizing global R&D gaps.
Carbapenem-resistant, 3rd-gen cephalosporin-resistant Enterobacterales	Critical	Urgent (CRE)	Alignment. CDC combines in "CRE" category.
Extended-spectrum β-lactamase (ESBL)-producing Enterobacterales	High	Serious	WHO notes high global community burden.
Methicillin-resistant Staphylococcus aureus (MRSA)	High	Serious	CDC notes progress in reducing HA-MRSA.
Clostridioides difficile	Not included (non-AMR)	Urgent	CDC includes due to broad antibiotic use link.
Drug-resistant Mycobacterium tuberculosis	Critical (separate list)	Concerning (listed)	WHO integrates into BPPL; CDC lists separately.
Drug-resistant Neisseria gonorrhoeae	High	Concerning	WHO ranks higher based on global spread and pipeline emptiness.
Candida auris	Not included (fungus)	Urgent	CDC's inclusion highlights emerging multi-drug resistant fungi.

Diagram 1: Priority Pathogen List Development Workflow

Both lists rely on a hierarchy of evidence, but with different geographic emphases.

Table 3: Primary Data Sources Compared

Data Type	WHO BPPL Primary Sources	CDC Threats Primary Sources
Global Surveillance	WHO GLASS, ATLAS, regional networks (e.g., EARS-Net)	N/A (Global data used for context)
National Surveillance	Member State reports (to GLASS)	U.S. NHSN, NARMS, AR Lab Network
Burden Estimates	Global Burden of Disease (IHME), published meta-analyses	CDC Epicenter models, U.S. hospital data
R&D Pipeline	WHO preclinical/clinical pipeline reviews, GARDP reports	Pew Charitable Trusts, FDA databases, literature
Expert Elicitation	Structured panels using modified Delphi process	Internal and external subject matter experts

Diagram 2: AMR Data Integration for Priority Setting

The Scientist's Toolkit: Research Reagent Solutions for Priority Pathogen Studies

Table 4: Essential Reagents and Resources

Item / Solution	Function in Priority Pathogen Research
CLSI / EUCAST Breakpoint Strips & Panels	Standardized antimicrobial susceptibility testing (AST) to define resistance profiles.
Whole Genome Sequencing (WGS) Kits (e.g., Illumina, Oxford Nanopore)	Identification of resistance determinants (genes, mutations), strain typing, and outbreak investigation.
Synthetic Human Serum / Biofilm Media	In vitro simulation of infection conditions for more relevant efficacy testing of novel compounds.
Galleria mellonella or Murine Infection Models	In vivo models to study pathogenesis and therapeutic efficacy for priority pathogens like CRAB and CRE.
CRISPR-Cas9 or Transposon Mutagenesis Systems	Functional genomics to identify and validate novel drug targets and resistance mechanisms.
Chemical Libraries (e.g., FDA-approved drugs, diversity libraries)	Screening for repurposing candidates and novel scaffolds active against priority pathogens.
Immunoassays for Virulence Factors (e.g., ELISA kits)	Quantifying expression of toxins and other virulence mechanisms that impact patient outcomes.
Bioinformatics Databases: CARD, NCBI AMRFinder, PATRIC, BV-BRC	In silico analysis of genomic AMR data and comparative genomics.

The WHO BPPL and CDC Threats List serve complementary roles. The WHO list is a forward-looking, R&D-focused global tool that uses a structured, weighted-criteria model to steer the international drug development pipeline. The CDC list is a public health action-oriented domestic tool that quantifies the immediate U.S. burden to guide prevention and response. For researchers, the choice of framework depends on the intended application: target selection for novel antibiotics aligns closely with the WHO BPPL, while studies on the epidemiology, transmission, and clinical management of AMR within the U.S. may find the CDC framework more relevant. Both, however, converge on a core group of gram-negative, multidrug-resistant bacteria representing the most pressing challenges in the field.

This guide compares the publication cycles, update triggers, and evidence integration mechanisms of the World Health Organization Bacterial Priority Pathogens List (WHO BPPL) and the U.S. Centers for Disease Control and Prevention's (CDC) Antibiotic Resistance Threats Report.

Table 1: Core List Publication Cycles and Drivers

Aspect	WHO Bacterial Priority Pathogens List (BPPL)	CDC Antibiotic Resistance Threats Report
Primary Publishing Agency	World Health Organization (WHO)	U.S. Centers for Disease Control and Prevention (CDC)
Core Publication Cycle	Approximately 5-7 years (1st ed. 2017, 2nd ed. 2024)	Approximately 3-5 years (2013, 2019, 2022 update)
Primary Update Trigger	Global public health need; advances in antibacterial R&D pipeline; emerging resistance epidemiology.	National (U.S.) surveillance data trends; new resistance mechanism emergence; changes in threat level impact.
Key Data Inputs	Global surveillance (GLASS, INSPEAR), burden of disease (DALYs), treatment feasibility, R&D pipeline analysis.	U.S. National Healthcare Safety Network (NHSN), Emerging Infections Program (EIP), National Antimicrobial Resistance Monitoring System (NARMS).
Primary Audience & Aim	Global policymakers, public health agencies, non-profit R&D funders. Guides global R&D priorities.	U.S. public health officials, healthcare providers, policymakers. Guides national prevention & control funding.
Categorization Framework	Priority tiers: Critical, High, Medium. Based on R&D urgency and key resistance criteria.	Threat levels: Urgent, Serious, Concerning. Based on impact (burden, transmissibility, treatability).
Integration of Economic Data	Indirectly via burden of disease and healthcare cost studies.	Explicitly includes economic burden estimates (direct medical costs).

Table 2: Evidence Synthesis & Update Methodology

Methodology Phase	WHO BPPL Process	CDC Threats Report Process
1. Evidence Assembly	Systematic reviews commissioned via WHO Advisory Group. Global expert network surveys (e.g., Delphi method).	Comprehensive analysis of U.S. multi-source surveillance data. Commissioned expert reviews on specific pathogens.
2. Criteria Weighting & Scoring	Multi-Criteria Decision Analysis (MCDA) using standardized score sheets. Criteria include mortality, treatability, transmission, R&D pipeline.	Quantitative data (incidence, mortality, costs) combined with qualitative expert assessment of threat characteristics.
3. Consensus & Review	Meetings of WHO Expert Advisory Group. Iterative review and ranking. Final approval by WHO leadership.	Interagency collaboration (FDA, USDA). External review by academic and public health experts. Internal CDC clearance.
4. Output & Dissemination	Publication of ranked list in WHO report and peer-reviewed journal (e.g., Lancet). Accompanying R&D guidance.	Full report publication, fact sheets, infographics. Data published in CDC's Antimicrobial Resistance Threats in the United States.

Experimental Protocols for List Development

Protocol 1: Multi-Criteria Decision Analysis (MCDA) for Pathogen Prioritization (WHO BPPL)

• Criteria Definition: A fixed set of criteria is established (e.g., attributable mortality, hospital vs. community spread, transmissibility, treatability, R&D pipeline status).
• Evidence Review: For each pathogen, a systematic literature review is conducted to gather data for each criterion.
• Scoring: Independent experts score each pathogen (typically on a scale of 1-5 or 1-9) for every criterion using standardized forms.
• Weighting: Experts assign relative weights to each criterion based on its perceived importance for global public health and R&D prioritization.
• Aggregation & Ranking: Scores and weights are aggregated mathematically (e.g., linear additive model) to generate a total score for each pathogen, which informs the final priority ranking.

Protocol 2: Integrated Surveillance Data Analysis for Threat Assessment (CDC)

• Data Harvesting: Aggregate and reconcile data from core surveillance systems (NHSN, EIP, NARMS) and other sources (e.g., National Tuberculosis Surveillance System).
• Burden Estimation: Calculate incidence, prevalence, morbidity, and mortality for resistant infections. Use statistical models (e.g., regression, simulation) to estimate the proportion of burden attributable to antimicrobial resistance (AMR).
• Economic Modeling: Apply cost-of-illness models using healthcare utilization data to estimate direct medical costs associated with resistant infections.
• Trend Analysis: Analyze longitudinal data (minimum 3-5 years) to identify statistically significant increases or decreases in resistance incidence or burden.
• Expert Elicitation: Convene subject matter experts to review integrated data and qualitative factors (e.g., emergence of new resistance genes, availability of new drugs) to assign final threat categories (Urgent, Serious, Concerning).

Visualization of List Development Workflows

The Scientist's Toolkit: Research Reagent Solutions for AMR Prioritization Studies

Table 3: Essential Materials for Surveillance & Prioritization Research

Reagent / Tool	Primary Function in Context
Standardized Antimicrobial Susceptibility Testing (AST) Panels	Provides consistent, reproducible MIC data essential for tracking resistance trends across time and geography, forming the core input for surveillance systems like GLASS and NHSN.
Whole Genome Sequencing (WGS) Kits & Platforms	Enables high-resolution detection of resistance genes, plasmids, and clonal lineages, critical for understanding transmission dynamics and emerging threats (e.g., Candida auris, carbapenemase genes).
Bioinformatics Pipelines (e.g., AMRFinderPlus, ResFinder)	Software tools for analyzing WGS data to identify known resistance determinants and predict phenotypic resistance, automating data flow from lab to public health databases.
Burden of Disease Models (e.g., DALY Calculation Frameworks)	Quantitative models that integrate mortality and morbidity data to estimate the total health burden of resistant infections, a key input for WHO's MCDA process.
Expert Elicitation Protocols	Structured questionnaires and facilitation guides (e.g., Delphi method) used to formally gather and reconcile judgments from international experts on criteria weighting and threat assessment.
Multi-Criteria Decision Analysis (MCDA) Software	Analytical tools (e.g., 1000minds, M-MACBETH) that support the scoring, weighting, and mathematical aggregation of complex criteria during priority-setting exercises.

From List to Lab: Translating Priority Pathogens into R&D Strategy and Public Health Policy

This guide compares the World Health Organization (WHO) Bacterial Priority Pathogens List (BPPL) and the U.S. Centers for Disease Control and Prevention (CDC) Antibiotic Resistance Threats List as strategic tools for prioritizing research and development (R&D) investment in antibacterial drug discovery. Framed within the broader thesis that the WHO BPPL is a superior global R&D prioritization instrument, this article objectively compares the two frameworks' performance in directing scientific resources.

Comparative Analysis of Prioritization Frameworks

Table 1: Core Structural Comparison of WHO BPPL vs. CDC Threats List

Feature	WHO Bacterial Priority Pathogens List (BPPL)	CDC Antibiotic Resistance Threats List
Primary Purpose	Guide R&D for new antibiotics and treatments.	Inform U.S. public health action and prevention.
Global Scope	Explicitly global, considers worldwide burden and spread.	Primarily U.S.-focused, though with global implications.
Categorization	Critical, High, Medium priority based on R&D needs.	Urgent, Serious, Concerning threats based on domestic impact.
Pathogen Focus	Bacteria and bacterial-drug combinations.	Bacteria, fungi, and other antimicrobial-resistant pathogens.
Update Cadence	2024 (latest update).	2019 (latest update; 2022 report focused on COVID-19 impact).
Key Metrics	Antibiotic resistance, mortality, transmissibility, treatability, R&D pipeline status.	Number of infections, deaths, transmissibility, available treatments, prevention barriers.

Table 2: Alignment of Pathogen Priorities (Critical/Urgent Tiers)

Pathogen / Resistance Threat	WHO BPPL 2024 Category	CDC 2019 Threats List Category	Concordance Level
Carbapenem-resistant Acinetobacter baumannii	Critical	Urgent	Full
Carbapenem-resistant Pseudomonas aeruginosa	Critical	Serious	Partial
Carbapenem-resistant, 3rd-gen cephalosporin-resistant Enterobacterales	Critical	Urgent (for some species)	High
Methicillin-resistant Staphylococcus aureus (MRSA)	High	Serious	Partial
Clostridioides difficile	Not included (non-target pathogen)	Urgent	None

Experimental Protocol: Assessing R&D Pipeline Alignment

A key experiment to validate the utility of the WHO BPPL as an R&D tool involves analyzing the alignment of the current clinical antibacterial pipeline with the list's priorities.

Methodology:

• Data Source Identification: Extract list of antibacterial agents in clinical development (Phase 1-3) from reputable databases (e.g., WHO Antibacterial Pipeline, Pew Charitable Trusts).
• Target Pathogen Mapping: For each agent, document its spectrum of activity, specifically against pathogens listed in the WHO BPPL 2024 and CDC 2019 list.
• Gap Analysis: Categorize agents based on whether they target WHO "Critical" priority pathogens. Calculate the percentage of the pipeline addressing the highest priority needs.
• Impact Projection: Cross-reference pipeline data with clinical need assessments (e.g., WHO-defined target product profiles) to identify remaining critical gaps.

Table 3: Snapshot of Clinical Pipeline Alignment (Illustrative Data)

WHO BPPL 2024 Critical Priority Pathogen	Number of Antibacterial Agents in Active Clinical Development (Phase 1-3)	Agents with Novel Mechanisms (non-derivative)	Notable Gaps Identified
CR Acinetobacter baumannii	~15-20	3-5	Oral formulations, drugs against pandrug-resistant strains
CR Pseudomonas aeruginosa	~10-15	2-4	Narrow-spectrum agents, resistance-breaker combinations
CR Enterobacterales	~20-25	4-6	Need for agents targeting specific enzymatic resistance (e.g., MBLs)
Total Pipeline Agents (All Targets)	~70-80	~15	--

Title: Workflow for R&D Priority Analysis Using WHO/CDC Lists

The Scientist's Toolkit: Key Research Reagent Solutions

Table 4: Essential Reagents for BPPL-Pathogen Research

Research Reagent / Material	Function in Experimental Discovery	Example Application
Cation-adjusted Mueller-Hinton Broth (CAMHB)	Standardized medium for antibiotic susceptibility testing (AST).	Determining MICs against WHO Critical pathogens.
CRISPR-Cas9 Gene Editing Systems	Precise genetic manipulation of bacterial pathogens.	Validating novel drug targets in A. baumannii or P. aeruginosa.
Galleria mellonella Larvae Model	Invertebrate host model for initial in vivo efficacy and toxicity screening.	Pre-mammalian testing of lead compounds against resistant infections.
Porcine Sputum Medium (PSM)	Synthetic cystic fibrosis sputum mimic for biofilm growth.	Studying drug penetration against P. aeruginosa biofilms.
Lux Reporter Gene Constructs	Bioluminescent markers for real-time monitoring of bacterial burden.	In vivo efficacy studies in murine thigh or lung infection models.
Human Serum	Ex vivo medium to study protein binding and bactericidal activity.	Assessing compound activity under physiologically relevant conditions.

Visualizing the WHO BPPL's Strategic Logic

Title: WHO BPPL Logic Chain for Directing Drug Discovery

The experimental pipeline analysis demonstrates that the WHO BPPL 2024, with its explicit global R&D focus, current data, and clear stratification based on antibacterial development need, provides a more targeted and actionable framework for directing scientific investment compared to the CDC list, which serves a vital but different public health monitoring purpose. Utilizing the provided protocols and toolkits, researchers can design discovery programs that directly address the most pressing unmet medical needs as defined by this global priority-setting tool.

Selecting target pathogens for clinical trials in antibacterial drug development is a critical strategic decision. This guide compares two major frameworks used to inform this selection: the World Health Organization (WHO) Bacterial Priority Pathogens List (BPPL) and the U.S. Centers for Disease Control and Prevention (CDC) Antibiotic Resistance Threats list. A data-driven comparison of their methodologies, prioritization tiers, and resulting pathogen rankings is essential for aligning trial design with global public health needs.

Comparative Analysis of Priority Pathogen Lists

Table 1: Framework Overview & Methodology Comparison

Feature	WHO Bacterial Priority Pathogens List (BPPL)	CDC Antibiotic Resistance Threats List
Primary Scope	Global, emphasizing public health impact and R&D needs worldwide.	National (U.S.), focusing on domestic burden and containment.
Last Update	2024 (2nd edition)	2019 (AR Threats Report); 2022 (Special Report on COVID-19 Impact)
Key Criteria	Mortality, morbidity, prevalence of resistance, transmissibility, treatability, prevention potential, 10-year R&D pipeline.	Number of infections, deaths, preventability, transmissibility, availability of effective antibiotics, trends.
Categorization	Critical, High, Medium priority tiers.	Urgent, Serious, Concerning threat levels; "Watch List."
Pathogen Focus	Bacterial and mycobacterial pathogens only.	Includes bacterial, fungal, and emerging pathogen threats.

Table 2: Pathogen Priority Tier Alignment (Examples)

Pathogen	WHO BPPL 2024 Tier	CDC AR Threats 2019 Tier	Key Resistance Concerns
Acinetobacter baumannii (carbapenem-resistant)	Critical	Urgent	Carbapenems, cephalosporins, fluoroquinolones
Pseudomonas aeruginosa (carbapenem-resistant)	Critical	Serious	Carbapenems, multidrug resistance
Enterococcus faecium (vancomycin-resistant)	Critical	Serious	Vancomycin, ampicillin
Staphylococcus aureus (methicillin-resistant, MRSA)	High	Serious	Beta-lactams, emerging vancomycin resistance
Helicobacter pylori (clarithromycin-resistant)	High	Watch List	Clarithromycin, metronidazole
Streptococcus pneumoniae (penicillin-non-susceptible)	Medium	Concerning	Penicillin, macrolides

Table 3: Quantitative Comparison of Priority Pathogens

Metric	WHO BPPL 2024 (Critical Tier)	CDC AR Threats 2019 (Urgent Tier)
Number of Bacterial Pathogens Listed	15 families across 3 tiers	5 listed as "Urgent" bacterial threats
Common Critical/Urgent Pathogens	4 (A. baumannii, P. aeruginosa, Enterobacteriaceae, E. faecium)	3 (A. baumannii, C. difficile, Enterobacteriaceae)
Estimated Annual U.S. Deaths (CDC Data)	~13,100 (for pathogens also in CDC Urgent)	~50,000 (all AR infections, all threat levels)
R&D Pipeline Emphasis	Explicitly weighted criterion	Implicitly considered

Experimental Protocols for Generating Supporting Data

The prioritization in these lists is informed by systematic reviews and data aggregation. The following outlines a generalized protocol for generating the burden and resistance data that underpin such lists.

Protocol 1: Global Antimicrobial Resistance Surveillance System (GLASS)-Informed Burden Study

• Objective: To estimate the incidence, mortality, and resistance prevalence of a target pathogen in a defined population.
• Specimen Collection: Collect clinical isolates from sterile and non-sterile sites per standardized case definitions (e.g., WHO/CDC protocols) across sentinel surveillance sites.
• Microbiological Analysis:
  • Isolate pathogens using culture media specified for target organism (e.g., chromogenic agar for MRSA).
  • Perform species confirmation via MALDI-TOF mass spectrometry.
  • Conduct antimicrobial susceptibility testing (AST) via broth microdilution (reference method) or automated systems, following CLSI or EUCAST breakpoints.
• Data Analysis:
  • Calculate incidence per 100,000 patient-days or population.
  • Determine all-cause mortality attributable to the infection.
  • Compute percentage of isolates resistant to key "watch" and "reserve" antibiotics (e.g., carbapenems, 3rd-gen cephalosporins).
• Meta-Analysis: Pool data from multiple surveillance studies using a random-effects model to generate global or regional estimates, adjusting for study heterogeneity.

Protocol 2: In Vitro Checkerboard Assay for Synergy Testing

• Objective: To evaluate the synergistic potential of a novel drug candidate with existing antibiotics against a priority-tier pathogen.
• Preparation:
  • Prepare serial two-fold dilutions of Drug A and Drug B in cation-adjusted Mueller-Hinton broth (CAMHB) in a 96-well microtiter plate, creating a matrix of concentration combinations.
  • Standardize a bacterial inoculum of the target pathogen (e.g., carbapenem-resistant A. baumannii) to 5 x 10^5 CFU/mL.
• Inoculation & Incubation: Add the bacterial suspension to each well. Include growth and sterility controls. Incubate at 35°C ± 2°C for 16-20 hours.
• Analysis: Determine the Fractional Inhibitory Concentration Index (FICI).
  • FICI = (MIC of Drug A in combo / MIC of Drug A alone) + (MIC of Drug B in combo / MIC of Drug B alone).
  • Interpretation: FICI ≤ 0.5 = synergy; >0.5 to ≤4 = no interaction; >4 = antagonism.
• Validation: Perform time-kill curve assays on synergistic combinations to confirm bactericidal activity over 24 hours.

Visualizing the Clinical Trial Design Framework

Title: Priority Pathogen Framework Informing Trial Design

The Scientist's Toolkit: Research Reagent Solutions

Table 4: Essential Materials for Priority Pathogen Research

Item	Function	Example Application
Cation-Adjusted Mueller-Hinton Broth (CAMHB)	Standardized medium for antimicrobial susceptibility testing (AST).	Broth microdilution for determining MICs per CLSI/EUCAST guidelines.
Chromogenic Agar	Selective and differential culture media for specific pathogen isolation.	Rapid screening for MRSA, VRE, or ESBL-producing Enterobacterales from surveillance samples.
AST Gradient Strips	Pre-formed antibiotic concentration gradients on plastic strips.	Etest for determining MICs of novel compounds or fastidious organisms.
MALDI-TOF Mass Spectrometry Reagents	Matrix and calibration standards for microbial identification.	Rapid, accurate species-level identification of bacterial isolates from clinical trials.
PCR Master Mix & Resistance Gene Primers	Enzymes and oligonucleotides for detecting specific resistance determinants.	Molecular confirmation of mecA (MRSA), blaKPC (carbapenemase), or other target genes.
In Vivo Infection Model Reagents	Specialized media, animal models, and inoculum preparation kits.	Pre-clinical efficacy testing of a lead compound against a WHO Critical-tier pathogen (e.g., neutropenic mouse thigh model).

Comparative Analysis of Pathogen Priority Frameworks: WHO BPPL vs. CDC AR Threats List

This guide provides a comparative evaluation of two major global and domestic pathogen priority lists: the World Health Organization (WHO) Bacterial Priority Pathogens List (BPPL) and the U.S. Centers for Disease Control and Prevention (CDC) Antibiotic Resistance Threats List. These frameworks direct research, funding, and public health policy, but differ in scope, methodology, and application.

Table 1: Framework Scope and Composition Comparison

Feature	WHO Bacterial Priority Pathogens List (BPPL)	CDC Antibiotic Resistance Threats List (2022)
Primary Focus	Global R&D priority for new antibiotics	Domestic public health threat assessment & action
Geographic Scope	Global, emphasizing global burden	United States-centric, based on U.S. data
Pathogen Scope	Bacteria only (15 priority pathogens across 3 tiers)	Bacteria & Fungi (19 specific pathogen threats across 3 urgency tiers)
Key Criteria	Drug resistance, mortality, prevalence, transmissibility, treatability, R&D pipeline	Burden (cases, deaths, cost), transmissibility, availability of prevention tools, magnitude of resistance, trends
Tier Structure	Critical, High, Medium	Urgent, Serious, Concerning
Inclusion of C. difficile	No (non-resistant pathogen)	Yes (Urgent threat, associated with antibiotic use)
Inclusion of Drug-Resistant Fungi	No	Yes (e.g., Candida auris - Urgent, Azole-resistant Aspergillus fumigatus - Concerning)

Table 2: Alignment and Divergence of Top-Tier Pathogens

WHO BPPL (Critical Tier)	CDC AR Threats List (Urgent Tier)	Alignment Status
Acinetobacter baumannii (carbapenem-resistant)	Acinetobacter (carbapenem-resistant)	Full
Pseudomonas aeruginosa (carbapenem-resistant)	Pseudomonas aeruginosa (carbapenem-resistant)	Full
Enterobacterales (carbapenem-resistant, 3rd-gen cephalosporin-resistant)	Carbapenem-resistant Enterobacterales (CRE)	Partial (CDC combines into one group)
	Candida auris (antifungal-resistant)	No WHO equivalent (fungus)
	Clostridioides difficile	No WHO equivalent (non-resistant pathogen)
	Neisseria gonorrhoeae (drug-resistant)	WHO: High Priority (not Critical)

Experimental Protocol for Burden of Disease Estimation (Comparative Methodology)

Objective: To quantify and compare the national burden of antibiotic-resistant infections as prioritized by the CDC list, replicable for WHO BPPL pathogens using local data.

Protocol:

• Data Source Identification: Utilize population-based surveillance networks (e.g., CDC's Emerging Infections Program - EIP) and the National Healthcare Safety Network (NHSN). For global comparisons, access WHO GLASS (Global Antimicrobial Resistance and Use Surveillance System) data.
• Case Definition: Apply standardized CDC case definitions for laboratory-confirmed antibiotic-resistant infections.
• Burden Calculation:
  • Incidence: Calculate number of cases per 100,000 population annually from EIP data.
  • Mortality: Attribute deaths using hospital discharge data and death certificates, applying the CDC's methodology for estimating deaths directly or indirectly attributable to infection.
  • Economic Cost: Use standardized cost models incorporating direct medical costs (length of stay, treatment) and societal costs (lost productivity). Costs are inflated to current USD.
• Trend Analysis: Use statistical models (e.g., Poisson regression) to analyze changes in incidence and mortality rates over a minimum 5-year period.
• Comparative Weighting: Assign threat categories (Urgent, Serious, Concerning) based on a composite score of burden, trend, and transmissibility.

Supporting Data: The CDC's 2022 report estimates 2.8 million antimicrobial-resistant infections annually in the U.S., leading to 35,000+ deaths. In contrast, WHO estimates bacterial AMR directly caused 1.27 million deaths globally in 2019.

Visualization: Framework Development & Application Workflow

Title: Workflow for Pathogen Priority List Development & Impact

The Scientist's Toolkit: Key Research Reagent Solutions for Priority Pathogen Studies

Reagent / Material	Primary Function	Example Application in AMR Research
Cation-Adjusted Mueller-Hinton Broth (CAMHB)	Standardized medium for broth microdilution antimicrobial susceptibility testing (AST).	Determining MIC values for novel compounds against CDC/WHO priority pathogens.
PCR & Whole Genome Sequencing Kits	Detection of resistance genes (blaKPC, blaNDM, mecA) and high-resolution strain typing.	Tracking transmission of Urgent threats (e.g., CRE, C. auris) in hospital outbreaks.
In Vivo Infection Model Systems (e.g., murine neutropenic thigh, murine septicemia)	Preclinical evaluation of antibiotic efficacy and pharmacokinetic/pharmacodynamic (PK/PD) relationships.	Testing new antibiotics against Critical-tier A. baumannii or P. aeruginosa.
Biofilm Assay Kits (e.g., microtiter plate crystal violet assay)	Quantification of biofilm formation, a key virulence factor in device-related infections.	Studying persistence of P. aeruginosa (Serious threat) on medical implants.
Human Serum or Plasma	Ex vivo modeling of protein binding and its impact on antibiotic activity under physiological conditions.	Assessing drug efficacy in a more clinically relevant matrix for S. aureus isolates.
Reporter Strain Panels (e.g., bioluminescent bacterial strains)	Real-time, non-invasive monitoring of infection burden and treatment response in animal models.	Accelerating in vivo efficacy studies for multiple WHO BPPL pathogen classes.

Table 3: Influence on Drug Development Pipelines: A Quantitative Snapshot

Metric	Influence of WHO BPPL	Influence of CDC Threats List
Clinical Trial Design	Guides inclusion of pathogens in multinational trials for novel antibiotics.	Informs trial sites and epidemiology for U.S.-focused trials (e.g., targeting community-acquired ESBLs).
FDA Designation Eligibility	Pathogens listed support eligibility for Qualified Infectious Disease Product (QIDP) designation.	U.S. threat level data supports Fast Track designation arguments to FDA.
Public Funding Allocation	Referenced by global funders (e.g., CARB-X) for project prioritization.	Directs NIH/NIAID research grant calls and contract areas (e.g., NIAID's Preclinical Services).
Pipeline Analysis (Example)	As of 2023, ~40% of clinical-stage antibacterial agents target at least one WHO Critical pathogen.	Over 50% of antibacterial agents with QIDP designation target a CDC Urgent or Serious threat pathogen.

The WHO BPPL and CDC Threats List are complementary tools. The WHO BPPL is the essential framework for global R&D strategy, identifying unmet needs to drive antibacterial innovation. The CDC list is the indispensable domestic action and prevention blueprint, providing the granular, national surveillance data required for implementing effective stewardship, infection control, and measuring public health outcomes. Successful drug development and infection prevention strategies require integration of both perspectives: targeting the globally recognized priority pathogens with interventions validated against the specific, data-driven threats within the key U.S. market.

Leveraging Both Lists for Grant Proposals and Justifying Research Priorities

Within the global public health landscape, the World Health Organization's Bacterial Priority Pathogens List (WHO BPPL) and the U.S. Centers for Disease Control and Prevention's Antibiotic Resistance Threats Report (CDC AR Threats List) serve as critical, complementary frameworks for guiding antimicrobial research and development. Grant proposals and research priority justifications are strengthened by directly referencing and integrating data from both lists. This comparison guide objectively analyzes how these frameworks perform as tools for directing experimental research, supported by data on their alignment and impact.

Comparative Analysis of List Composition and Prioritization Metrics

Table 1: Comparison of WHO BPPL 2024 and CDC AR Threats List 2019 (Updated 2022)

Criterion	WHO Bacterial Priority Pathogens List (2024)	CDC Antibiotic Resistance Threats List (2019, 2022 Update)
Primary Scope	Global, public health-focused R&D prioritization.	U.S.-centric, public health surveillance and action.
Categorization	Priority 1 (Critical), 2 (High), 3 (Medium).	Urgent, Serious, Concerning, Watch List.
Key Pathogens (Critical/Urgent Tier)	Acinetobacter baumannii (carbapenem-resistant), Pseudomonas aeruginosa (carbapenem-resistant), Enterobacterales (carbapenem-resistant, ESBL-producing).	Candida auris, Clostridioides difficile, Carbapenem-resistant Acinetobacter, Drug-resistant Neisseria gonorrhoeae.
Prioritization Metrics	Mortality, treatability, transmissibility, prevalence, ten-year trend of resistance, pipeline.	Infection burden, healthcare cost, transmissibility, treatability, prevention potential.
Primary Audience	Global policymakers, public health R&D funders, academic researchers.	U.S. public health agencies, healthcare providers, local policymakers.

Table 2: Alignment of Pathogen Rankings and Grant Justification Leverage

Pathogen / Resistance Profile	WHO BPPL 2024 Ranking	CDC AR Threats List Ranking	Strategic Leverage for Proposals
Carbapenem-resistant Acinetobacter baumannii	Priority 1: Critical	Urgent	High Alignment. Justify basic research on novel targets and preclinical drug development.
Carbapenem-resistant Pseudomonas aeruginosa	Priority 1: Critical	Serious	Strong Alignment. Support for mechanism of resistance studies and alternative therapeutic strategies.
ESBL-producing Enterobacterales	Priority 1: Critical	Serious	Strong Alignment. Rationale for rapid diagnostics, epidemiology, and non-traditional antimicrobials.
Drug-resistant Mycobacterium tuberculosis	Priority 2: High	Not Listed (separate program)	Contextual. Use WHO for global proposals; cite CDC data on domestic TB for U.S.-focused work.
Clostridioides difficile	Not Listed (non-traditional)	Urgent	Complementary. CDC listing justifies research; WHO exclusion highlights need for non-antibiotic approaches.

Experimental Protocols for Comparative Validation Studies

Protocol 1: In Vitro Potency Screening Against Priority Pathogens

• Objective: To compare the efficacy of a novel compound against bacterial strains designated by both the WHO and CDC lists.
• Methodology:
  • Bacterial Strains: Procure reference and clinically isolated strains of A. baumannii (carbapenem-resistant), P. aeruginosa (carbapenem-resistant), and ESBL-producing E. coli.
  • Compound Preparation: Prepare serial two-fold dilutions of the test compound and standard-of-care antibiotics (e.g., meropenem, colistin) in cation-adjusted Mueller-Hinton broth.
  • Broth Microdilution: Inoculate wells with ~5 x 10^5 CFU/mL of each bacterial strain. Incubate at 35°C for 16-20 hours.
  • Endpoint Determination: Determine the Minimum Inhibitory Concentration (MIC) as the lowest concentration that inhibits visible growth. Perform in triplicate.
  • Data Analysis: Compare MIC50/90 values across pathogen panels. Correlate potency gaps with the priority rankings from each list.

Protocol 2: In Vivo Efficacy in a Neutropenic Murine Thigh Model

• Objective: To validate the in vivo therapeutic potential of a candidate drug against a WHO Priority 1 / CDC Urgent pathogen.
• Methodology:
  • Animal Model: Render mice neutropenic via cyclophosphamide administration.
  • Infection: Inoculate thighs with a defined CFU of a carbapenem-resistant A. baumannii clinical isolate.
  • Treatment: Initiate therapy with the candidate drug, a comparator antibiotic, or placebo at 2 hours post-infection. Administer doses subcutaneously or intravenously.
  • Assessment: Sacrifice animals at 24 hours. Harvest thigh tissues, homogenize, and plate serial dilutions for quantitative CFU counts.
  • Statistical Analysis: Compare mean bacterial burden reduction (log10 CFU/thigh) between treatment groups using ANOVA. A ≥1 log reduction vs. placebo is considered significant.

Visualizing the Strategic Integration Framework

Title: Integrating WHO and CDC Lists for Research Strategy

Title: Experimental Workflow for Validating vs Priority Lists

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for Priority Pathogen Research

Item	Function & Application	Example/Supplier Consideration
CDC & FDA AR Isolate Bank Panels	Provides characterized, clinically relevant strains matching threat list rankings for in vitro assays.	CDC's AR Isolate Bank (A. baumannii, P. aeruginosa panels).
ATCC Priority Pathogen Strains	Well-documented reference strains for standardized benchmarking and reproducibility.	ATCC BAA-1605 (CRAB), ATCC BAA-2108 (CRE).
Cation-Adjusted Mueller Hinton Broth (CAMHB)	Standardized medium for reliable, reproducible broth microdilution MIC testing per CLSI guidelines.	Various microbiological media suppliers (e.g., BD, Oxoid).
Premade MIC Panels	96-well plates with pre-dispensed antibiotic gradients for high-throughput screening.	Thermo Fisher Sensititre, MICRONAUT MIC plates.
Murine Neutropenic Thigh Infection Model Kit	Standardized reagents (e.g., cyclophosphamide) for establishing the in vivo efficacy model.	Cyclophosphamide from pharmaceutical or research chemical suppliers.
Clinical & Laboratory Standards Institute (CLSI) Documents	Definitive guidelines (M07, M100) for performing and interpreting antimicrobial susceptibility tests.	Critical for methodological rigor in grant proposals.
Whole Genome Sequencing Services	To confirm strain identity, resistance mechanisms, and genetic stability pre-/post-experiment.	Core facilities or commercial providers (e.g., Illumina, Oxford Nanopore).

Navigating Gaps and Challenges: Limitations and Strategic Considerations for Professionals

Within the ongoing research discourse comparing the World Health Organization's Bacterial Priority Pathogens List (WHO BPPL) and the U.S. Centers for Disease Control and Prevention's (CDC) Antibiotic Resistance Threats list, a significant gap is the explicit focus on bacterial agents. This leaves critical threats from non-bacterial antimicrobial resistance (AMR) pathogens—namely fungi, viruses, and parasites—under-prioritized in global surveillance and drug development agendas. This comparison guide evaluates experimental platforms for characterizing resistance in these overlooked pathogens.

Comparison of Non-bacterial AMR Threat Assessment Platforms

Table 1: Comparative Analysis of Experimental Platforms for Non-bacterial AMR Profiling

Platform/Assay	Target Pathogen Class	Key Measurable Output	Throughput	Data Integration Potential (with BPPL frameworks)	Primary Limitation
Broth Microdilution (CLSI M27/M38)	Fungi (e.g., Candida auris, Aspergillus fumigatus)	Minimum Inhibitory Concentration (MIC) for antifungals	Medium	High (directly analogous to bacterial MIC)	Limited to cultivable fungi; static concentration.
Plaque Reduction Assay (PRA)	Viruses (e.g., Acyclovir-resistant HSV, HCV NS5A variants)	IC50 (concentration inhibiting 50% plaque formation)	Low	Medium (requires adaptation of breakpoint concepts)	Labor-intensive; cell line-dependent.
SYBR Green I Drug Sensitivity Assay	Malaria Parasites (Plasmodium falciparum)	IC50 for antimalarials (e.g., artemisinin)	High	Medium (quantitative but parasite-specific)	Requires fluorescence-capable equipment.
Whole Genome Sequencing (WGS) + SNP Analysis	Fungi, Viruses, Parasites	Mutations associated with resistance (e.g., ERG11, POL gene, kelch13)	High	Very High (enables unified genetic surveillance)	Correlative; requires functional validation.
Time-Kill Kinetics Assay	Fungi	Fungicidal vs. Fungistatic activity over time	Low	High (pharmacodynamic modeling)	Time-point intensive; low throughput.

Experimental Protocols for Key Non-bacterial AMR Assays

Protocol 1: Broth Microdilution for Antifungal Susceptibility Testing (Adapted from CLSI M27)

• Preparation: Prepare RPMI 1640 broth medium (with MOPS buffer, pH 7.0). Prepare stock solutions of antifungals (e.g., fluconazole, amphotericin B) in specified solvents.
• Dilution: Perform two-fold serial dilutions of antifungals in 96-well microdilution trays using an automated liquid handler to ensure precision. Final concentrations typically range from 0.03 to 16 µg/mL.
• Inoculation: Prepare fungal inoculum suspension (e.g., Candida spp.) adjusted to a 0.5 McFarland standard, then further dilute in broth to yield a final concentration of 0.5 x 10³ to 2.5 x 10³ CFU/mL in each well.
• Incubation: Seal trays and incubate at 35°C for 24-48 hours (species-dependent) without agitation.
• Reading: Determine the MIC visually. For azoles, the MIC is the lowest concentration showing ~50% growth inhibition relative to the drug-free control well. For amphotericin B, it is the lowest concentration showing 100% inhibition.

Protocol 2: Plaque Reduction Assay for Antiviral Resistance

• Cell Seeding: Seed confluent monolayers of permissive cells (e.g., Vero cells for HSV) in 12-well tissue culture plates.
• Virus Infection & Drug Exposure: Dilute virus stock to a concentration yielding ~50-100 plaques per well. Mix equal volumes of diluted virus with serial dilutions of the antiviral drug (e.g., acyclovir). Incubate the virus-drug mixture for 1 hour at 37°C.
• Inoculation: Aspirate media from cell monolayers. Apply the 200 µL virus-drug mixture to each well in duplicate. Adsorb for 1 hour with gentle rocking every 15 minutes.
• Overlay: Add a semi-solid overlay medium (e.g., carboxymethylcellulose or agarose in maintenance medium) to restrict virus spread to neighboring cells.
• Incubation & Staining: Incubate plates for 48-72 hours. Fix cells with formaldehyde and stain with crystal violet to visualize clear plaques against a background of stained, live cells.
• Analysis: Count plaques. Calculate the percentage reduction in plaque formation relative to the no-drug control. Determine the IC50 using non-linear regression analysis (e.g., probit model).

Visualization of Research Workflows

Title: Integrated Non-bacterial AMR Research Workflow

Title: Key Non-bacterial AMR Genetic Markers

The Scientist's Toolkit: Research Reagent Solutions

Table 2: Essential Reagents for Non-bacterial AMR Research

Item	Function in Research	Example Application
RPMI 1640 with MOPS Buffer	Standardized medium for antifungal susceptibility testing, maintains stable pH during incubation.	CLSI-compliant broth microdilution for Candida and Aspergillus.
Antifungal & Antiviral Drug Standards	Provide precise, quality-controlled reference compounds for generating accurate dose-response curves.	Preparing serial dilutions for MIC/IC50 determination.
Carboxymethylcellulose (CMC) Overlay	Semi-solid overlay to confine viral spread for discrete plaque formation in antiviral assays.	Plaque reduction assays for Herpes Simplex Virus (HSV).
SYBR Green I Nucleic Acid Stain	Fluorescent dye that intercalates into parasite DNA for high-throughput viability readouts.	In vitro drug sensitivity assays for Plasmodium falciparum.
MagPure Fungal DNA Kit	Optimized for efficient cell lysis and genomic DNA extraction from tough fungal cell walls.	WGS of multidrug-resistant Candida auris isolates.
Next-Generation Sequencing Library Prep Kit	Prepares genetic material from diverse pathogens for whole genome or targeted sequencing.	Identifying resistance mutations in viral, fungal, or parasitic genomes.
Crystal Violet Stain Solution	Stains live, fixed cells for contrast in plaque-based viral titration assays.	Visualizing plaques in antiviral resistance testing.

This comparison guide examines the application of two critical antibiotic resistance priority pathogen lists—the World Health Organization (WHO) Bacterial Priority Pathogens List (BPPL) and the U.S. Centers for Disease Control and Prevention (CDC) Antibiotic Resistance Threats Report—in local and regional contexts. Framed within broader thesis research on global versus national prioritization, this guide provides an objective comparison of their utility for directing regional research and drug development, supported by experimental data on pathogen behavior and surveillance.

Comparative Analysis of Priority Pathogens

The following table summarizes the 2024 WHO BPPL and the 2019 CDC AR Threats Report (2022 update) rankings, highlighting key disconnects in pathogen prioritization that impact local research focus.

Table 1: Pathogen Priority Tier Comparison (WHO vs. CDC)

Pathogen	WHO BPPL 2024 Priority Tier	CDC 2019/2022 Threat Category	Notes on Regional Disconnect
Acinetobacter baumannii (carbapenem-resistant)	Critical (Priority 1)	Urgent	Strong alignment for high priority.
Enterococcus faecium (vancomycin-resistant)	High (Priority 2)	Serious	WHO tier reflects global spread; CDC categorizes based on US burden.
Helicobacter pylori (clarithromycin-resistant)	High (Priority 2)	Watch List	WHO highlights global gastric cancer link; less emphasized in US-centric list.
Salmonella spp. (fluoroquinolone-resistant)	Medium (Priority 3)	Serious	Divergence due to variable enteric fever burden in non-US regions.
Group A Streptococcus	Not Listed	Threat (Not in top tiers)	CDC cites rising US invasiveness; not a top-tier global R&D priority.
Candida auris	Not Listed (Fungal)	Urgent	CDC urgency due to US outbreaks; WHO BPPL is strictly bacterial.

Experimental Data on Regional Pathogen Behavior

To illustrate the practical implications of list discrepancies, we present comparative microbiological and genomic data from simulated regional surveillance studies.

Table 2: In Vitro Efficacy of Last-Line Agents by Region (Hypothetical Surveillance Data)

Pathogen (Resistance Profile)	Agent Tested	% Susceptible - SE Asia Isolate Pool (n=50)	% Susceptible - US Isolate Pool (n=50)	Experimental Protocol Reference
Carbapenem-resistant A. baumannii (CRAB)	Colistin	78%	92%	Protocol A (Broth Microdilution)
Carbapenem-resistant Pseudomonas aeruginosa (CRPA)	Ceftolozane-tazobactam	65%	88%	Protocol B (Disk Diffusion/Etest)
Vancomycin-resistant E. faecium (VRE)	Linezolid	95%	99%	Protocol A (Broth Microdilution)

Detailed Experimental Protocols

Protocol A: Broth Microdilution for MIC Determination

• Bacterial Inoculum: Prepare a 0.5 McFarland standard from fresh overnight colonies in saline. Dilute in cation-adjusted Mueller-Hinton broth (CAMHB) to achieve a final concentration of ~5 x 10^5 CFU/mL per well.
• Plate Preparation: Using a 96-well microtiter plate, perform two-fold serial dilutions of the antibiotic in CAMHB across rows. Include growth control (no antibiotic) and sterility control (no inoculum) wells.
• Inoculation & Incubation: Aliquot 100µL of the standardized inoculum into each test well. Seal plates and incubate at 35°C ± 2°C for 16-20 hours in ambient air.
• Endpoint Reading: Determine the Minimum Inhibitory Concentration (MIC) as the lowest antibiotic concentration that completely inhibits visible growth. Interpret results using current CLSI (US) or EUCAST (Global) breakpoints as regionally appropriate.

Protocol B: Combined Disk Diffusion and Etest Methodology for Surveillance

• Agar Plating: Swab standardized inoculum (0.5 McFarland) onto the entire surface of a 150mm Mueller-Hinton agar plate. Allow surface to dry for 15 minutes.
• Disk Application: Apply relevant antibiotic-impregnated disks (e.g., meropenem, ceftazidime-avibactam) to the plate using a sterile dispenser.
• Etest Strip Application: Apply an Etest gradient strip for the same antibiotic perpendicular to the disk, ensuring the strip's minimum concentration end is near the disk.
• Incubation & Analysis: Incubate at 35°C for 16-20 hours. Measure zone diameters (mm) from the disk and read the MIC (µg/mL) from the Etest strip intersection. This dual-method approach provides robust phenotypic confirmation.

Visualization of Research Workflow and List Impact

Diagram 1: Influence of Priority Lists on Local Research

Diagram 2: Regional AST Workflow with Breakpoint Disconnect

The Scientist's Toolkit: Key Research Reagent Solutions

Table 3: Essential Reagents for Comparative Resistance Studies

Item	Function in Protocol	Key Consideration for Regional Studies
Cation-Adjusted Mueller-Hinton Broth (CAMHB)	Standardized medium for broth microdilution AST. Ensures consistent cation concentrations (Ca2+, Mg2+) critical for aminoglycoside and polymyxin testing.	Must be sourced from reliable global suppliers to minimize batch variability when comparing data across labs.
EUCAST and CLSI Breakpoint Tables	Reference documents for interpreting MICs (µg/mL) and zone diameters (mm) as Susceptible (S), Intermediate (I), or Resistant (R).	The primary source of disconnect. Researchers must apply the standard relevant to their region and explicitly state which was used.
Quality Control Strain Panels	Frozen stocks of reference strains (e.g., E. coli ATCC 25922, P. aeruginosa ATCC 27853) with defined MIC ranges. Used to validate each AST run.	Essential for inter-laboratory comparability. Should be obtained from international culture collections (e.g., ATCC, NCTC).
PCR Master Mixes & Resistance Gene Panels	For confirmatory genotypic testing of detected resistance (e.g., blaKPC, mecA, vanA genes).	Panels should be customized based on local resistance epidemiology, not just WHO/CDC listed pathogens.
Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF MS) Reagents	Chemical matrices and calibration standards for rapid, accurate microbial identification to the species level.	Correct species ID is the critical first step. Database must be comprehensive and include regional variants.
Lyophilized Antibiotic Panels for MIC	Pre-formatted 96-well plates containing graded concentrations of multiple antibiotics.	Enables high-throughput screening. Panels should be configured based on local formulary and resistance patterns.

Antimicrobial resistance (AMR) surveillance is critical for guiding public health action and therapeutic development. Two foundational frameworks are the World Health Organization (WHO) Bacterial Priority Pathogens List (BPPL) and the U.S. Centers for Disease Control and Prevention (CDC) Antibiotic Resistance Threats report. This comparison guide evaluates the performance of a hypothetical Real-Time Genomic Surveillance Platform (RTGSP) against traditional, lagged surveillance methods within the context of these frameworks.

Performance Comparison: RTGSP vs. Traditional Surveillance

Metric	Real-Time Genomic Surveillance Platform (RTGSP)	Traditional Phenotypic Surveillance (Lag Model)	CDC/WHO List Utility
Data Latency	7-14 days from sample collection to report	30-90 days (aggregation, phenotyping, reporting)	Lists updated every 3-5 years; inherent lag.
Threat Detection Speed	Rapid identification of emerging resistance clones and plasmids.	Delayed; reliant on phenotypic expression and outbreak reporting.	Retrospectively confirms threats; limited predictive value.
Mechanism Resolution	High (Identifies specific resistance genes, SNPs, and plasmid vectors).	Low (Confirms resistance phenotype; requires additional work for mechanism).	Guides focus on pathogens/mechanisms but not strain dynamics.
Outbreak Linkage	Real-time, high-resolution cluster analysis.	Slow, often based on epidemiology and pulsed-field gel electrophoresis (PFGE).	Informs which resistant infections are most urgent.
Data for Drug Development	Provides evolving molecular targets and resistance trends.	Provides historical prevalence data of resistant phenotypes.	Prioritizes pathogens for new drug development.

Supporting Experimental Data: A simulated analysis was conducted to compare the time-to-detection for a novel Klebsiella pneumoniae carbapenemase (KPC) variant.

• RTGSP Protocol: Clinical isolates were subjected to whole-genome sequencing (WGS) on a platform like Illumina NextSeq. Data was processed through a bioinformatics pipeline (e.g., CARD, ResFinder, PLACNETw) for AMR gene detection and plasmid reconstruction. Alerts were generated for novel gene variants.
• Traditional Protocol: Isolates underwent automated broth microdilution (e.g., Beckman Coulter MicroScan) for phenotypic carbapenem resistance. Confirmatory testing (e.g., modified carbapenem inactivation method, mCIM) and subsequent PCR/Sanger sequencing for gene identification followed.

Event Timeline	RTGSP (WGS-based)	Traditional (Phenotype-first)
Day 0: Sample Collection	Sample Collected	Sample Collected
Day 2: Initial Result	WGS completed. Bioinformatic analysis flags a novel KPC variant.	Phenotypic resistance to meropenem confirmed.
Day 5: Confirmatory Result	Alert issued. Phylogenetic analysis links 3 regional cases.	mCIM test positive. Planned for batch sequencing.
Day 14: Public Health Report	Detailed report on variant, plasmid, and cluster published.	Sample sent to reference lab for sequencing.
Day 30: Final Report	N/A	Official report of novel variant generated.

The Scientist's Toolkit: Research Reagent Solutions

Item	Function in AMR Surveillance Research
Next-Generation Sequencer (e.g., Illumina NextSeq 2000)	Provides high-throughput, accurate whole-genome sequences for resistance gene and mutation detection.
Automated Antimicrobial Susceptibility System (e.g., BD Phoenix M50)	Delivers standardized phenotypic minimum inhibitory concentration (MIC) data, the clinical gold standard.
Resistance Gene Database (e.g., CARD, ResFinder)	Curated repositories of AMR genes and variants for bioinformatic annotation of WGS data.
Plasmid Assembly & Typing Tool (e.g., MOB-suite, PlasmidFinder)	Identifies and classifies plasmid sequences from WGS data, critical for tracking horizontal gene transfer.
CRISPR-based Detection Kit (e.g., SHERLOCK for specific AR genes)	Allows for rapid, point-of-need molecular confirmation of specific high-threat resistance mechanisms.

Visualization: Workflow & Conceptual Frameworks

Diagram 1: Real-Time vs. Lagged AMR Intelligence Workflow

Diagram 2: AMR Threat Intelligence Integration Pathway

The assessment of antimicrobial resistance (AMR) threats is a critical foundation for guiding research and public health investment. Two prominent frameworks are the World Health Organization (WHO) Bacterial Priority Pathogens List (WHO BPPL) and the U.S. Centers for Disease Control and Prevention’s (CDC) Antibiotic Resistance Threats report. This guide objectively compares these frameworks, not as competing products, but as strategic tools with differing scopes, methodologies, and outputs that shape the experimental and developmental landscape for researchers and drug development professionals.

Core Framework Comparison

Table 1: Structural & Methodological Comparison of WHO BPPL vs. CDC Threats List

Feature	WHO Bacterial Priority Pathogens List (BPPL)	CDC Antibiotic Resistance Threats Report
Primary Scope	Global; emphasizes pathogens with intrinsic resistance to last-resort antibiotics, guiding R&D of new treatments.	U.S.-centric; emphasizes domestic public health impact (burden, transmissibility, prevention potential).
Categorization Logic	Priority tiers (Critical, High, Medium) based on R&D urgency and antibiotic resistance profile.	Threat levels (Urgent, Serious, Concerning) based on composite of clinical and economic burden, trends, and transmissibility.
Key Input Factors	1. Mortality attributable to resistance.2. Complicated vs. uncomplicated treatment.3. Transmissibility, preventability in healthcare.4. 10-year new antibiotic pipeline.	1. Number of cases and deaths.2. Healthcare costs (direct, societal).3. Ease of spread (transmission dynamics).4. Availability of effective antibiotics (treatment landscape).5. Prevention and infection control barriers.
Pathogen Inclusion	Bacteria (and Mycobacterium tuberculosis) only.	Bacteria, fungi (e.g., Candida auris), and resistant parasites.
Explicit Host Consideration	Indirectly via healthcare-associated vs. community-acquired infection contexts.	Direct via population-specific burden data (e.g., age, comorbidities) and healthcare exposure risks.
Update Cycle	2017 (first list), updated in 2024.	2013, 2019, 2022 (COVID-19/Fungal update).

Experimental Data and Protocol: A Case Study onAcinetobacter baumannii

Both lists classify carbapenem-resistant Acinetobacter baumannii (CRAB) as a top-tier threat (WHO: Critical; CDC: Urgent). The following comparative experimental protocol illustrates how the frameworks' nuances influence research design.

Protocol: Evaluating Novel Combination Therapy Against CRAB in a Murine Pneumonia Model

Objective: To assess the efficacy of a novel β-lactam/β-lactamase inhibitor combination (Drug X) + polymyxin B against CRAB, incorporating host immune status and transmission potential metrics.

Methodology:

• Bacterial Strains & Inoculum Preparation:

  • Strains: CRAB clinical isolates (n=10), characterized for carbapenemase genes (OXA-23, NDM) and minimum inhibitory concentrations (MICs).
  • Preparation: Cultures grown to mid-log phase, washed, and suspended in PBS. Inoculum standardized to 1x10^7 CFU/mL for infection.

• Animal Model & Host Factor Integration:

  • Groups: 8-week-old, immunocompetent vs. neutropenic (cyclophosphamide pre-treated) mice (n=10/group).
  • Infection: Intranasal instillation under anesthesia to establish pneumonia.
  • Treatment Arms (initiated 2h post-infection): a) Saline control, b) Polymyxin B monotherapy (15 mg/kg/q12h), c) Drug X monotherapy (50 mg/kg/q8h), d) Combination therapy.

• Efficacy & Host Response Metrics:

  • Primary: Bacterial burden (CFU/g) in lungs at 24h.
  • Secondary: Survival over 7 days; host cytokine levels (IL-6, TNF-α) in lung homogenate via ELISA.
  • Statistical Analysis: ANOVA with post-hoc tests; Kaplan-Meier survival analysis.

• Transmission Dynamics Addendum (ex vivo):

  • Protocol: Soiled cage bedding from infected mice is placed in contact with naïve, sentinel mice for 48h.
  • Outcome: Nasal and rectal swabs from sentinel mice cultured to assess environmental persistence and indirect transmission potential of the infecting strain.

Diagram 1: CRAB Combination Therapy & Transmission Study Workflow

Supporting Data from Comparative Analysis:

Table 2: Simulated Experimental Outcomes Aligned to Framework Priorities

Measured Outcome	Representative Simulated Data (Mean ± SD)	Relevance to WHO BPPL	Relevance to CDC Threats List
Lung CFU/g (Immunocompetent)	Control: 8.5±0.3 log10Combo: 3.1±0.8 log10*	Demonstrates efficacy against a "Critical" pathogen with few treatment options.	Reduces burden, potentially decreasing mortality (burden metric).
Lung CFU/g (Neutropenic)	Control: 9.1±0.2 log10Combo: 5.4±1.1 log10*	Highlights challenge in vulnerable hosts, justifying R&D for robust therapies.	Informs threat level in immunocompromised populations (host factor).
7-Day Survival (Neutropenic)	Control: 0%Combo: 60%*	Addresses high mortality associated with resistant infections.	Directly links to death estimates, a core metric for "Urgent" threats.
Sentinel Mouse Colonization Rate	4/10 (40%) from Combo group bedding.	Indicates persistent environmental contamination post-treatment.	Directly measures "ease of spread" and environmental persistence (transmission dynamic).

Simulated data for illustrative comparison; *p<0.01 vs. Control.

The Scientist's Toolkit: Key Research Reagent Solutions

Table 3: Essential Materials for AMR Threat Characterization Studies

Item	Function in Research	Example Application in Protocol
CRAB Isolate Panel	Provides genotypically/phenotypically characterized strains for robust testing.	Inoculum preparation for infection model; represents clinical diversity.
Murine Neutropenia Induction Agent (e.g., Cyclophosphamide)	Models the compromised host immune state, a critical patient risk factor.	Creating the neutropenic cohort to test therapy under host-factor duress.
Specific Pathogen-Free (SPF) Mouse Housing	Controls for confounding infections and allows transmission studies.	Baseline for host response; required for the ex vivo transmission addendum.
Multiplex Cytokine ELISA Kit	Quantifies host inflammatory response, linking pathogenicity to treatment outcome.	Measuring IL-6, TNF-α in lung homogenates as secondary efficacy/host response metrics.
Automated MIC Testing System (e.g., ETEST, Broth Microdilution)	Generates reproducible, quantitative antibiotic susceptibility data.	Pre-screening bacterial isolates for resistance profiles prior to in vivo study.
Environmental Swab & Transport Media	Preserves viability of pathogens from environmental samples for culture.	Sampling soiled bedding for the transmission dynamics arm of the study.

The WHO BPPL and CDC Threats list are complementary frameworks. The WHO BPPL acts as a global R&D compass, prioritizing pathogens where the antibacterial pipeline is most barren. The CDC list serves as a detailed national public health action plan, quantifying burden and emphasizing prevention.

For researchers and drug developers, this comparison underscores the necessity of moving beyond simple pathogen lists. Effective therapeutic strategies must be evaluated through experiments that integrate host factors (like immune status), measure impact on transmission dynamics, and are contextualized within the real-world treatment landscape. Designing studies that address the criteria of both frameworks ensures research is both globally relevant and directly responsive to the multifaceted nature of the AMR crisis.

Comparative Analysis: Alignment, Divergence, and Complementary Roles of WHO and CDC Frameworks

This comparison guide objectively analyzes the alignment and divergence between the World Health Organization's Bacterial Priority Pathogens List (WHO BPPL) and the U.S. Centers for Disease Control and Prevention's Antibiotic Resistance Threats Report (CDC AR Threats List). This analysis is critical for prioritizing global and national research, surveillance, and drug development efforts.

Comparative Ranking Tables

Table 1: Critical/Urgent Threat Tier Overlap

Pathogen	WHO BPPL 2024 Rank	CDC AR Threats 2019 Rank	Key Discrepancy Note
Acinetobacter baumannii (carbapenem-resistant)	Priority 1: Critical	Urgent Threat	Strong alignment.
Enterobacteriaceae (carbapenem-resistant)	Priority 1: Critical	Urgent Threat	Strong alignment. WHO specifies Enterobacter spp.; CDC lists CRE broadly.
Pseudomonas aeruginosa (carbapenem-resistant)	Priority 1: Critical	Serious Threat	Major Discrepancy: WHO ranks higher, emphasizing global critical need for new agents.
Enterococcus faecium (vancomycin-resistant)	Priority 2: High	Serious Threat	Notable Discrepancy: WHO ranks VRE higher, reflecting greater concern in healthcare-associated infections globally.
Staphylococcus aureus (methicillin-resistant)	Priority 2: High	Serious Threat	CDC notes "concerning" progress; threat level remains high.
Neisseria gonorrhoeae (drug-resistant)	Priority 2: High	Urgent Threat	Strong alignment on threat, with CDC assigning highest tier in U.S. context.

Table 2: Notable Omissions & Unique Inclusions

List	Included Pathogen / Group	Rank	Rationale Context
WHO BPPL	Salmonella spp. (fluoroquinolone-resistant)	Priority 3: Medium	Global burden of foodborne disease, especially in low-resource settings.
WHO BPPL	Helicobacter pylori (clarithromycin-resistant)	Priority 2: High	Unique focus on non-invasive, chronic infection with growing resistance.
CDC AR Threats	Candida auris	Urgent Threat	Fungal threat; WHO BPPL is strictly bacterial. Highlights need for broad antimicrobial focus.
CDC AR Threats	Clostridioides difficile	Urgent Threat	Pathogen whose threat is driven by antibiotic use, not inherent resistance.
CDC AR Threats	Drug-resistant Mycobacterium tuberculosis	Not on 2019 list	Addressed in separate CDC report, while WHO BPPL includes it in Priority 1.

Experimental Protocols for Generating Ranking Evidence

The rankings are derived from synthesized data rather than a single experiment. Key methodological frameworks include:

Protocol 1: WHO BPPL Evidence Synthesis

• Data Collection: Systematic reviews of published literature and national surveillance reports on incidence, mortality, treatability, and resistance trends.
• Criteria Application: Each pathogen is scored against ten criteria:
  • Impact on Public Health: Mortality, morbidity, healthcare burden.
  • Antimicrobial Resistance: Current resistance rates, trend, transmissibility of resistance genes.
  • Treatability: Availability and effectiveness of existing antibiotics.
  • Prevention Potential: Feasibility of infection control and prevention.
• Delphi Process: A multi-round, structured consultation with an international panel of experts to finalize rankings based on the aggregated evidence.

Protocol 2: CDC AR Threat Level Assessment

• U.S. Surveillance Data Integration: Quantitative analysis of data from the National Healthcare Safety Network (NHSN), Emerging Infections Program (EIP), and other U.S.-centric systems.
• Scoring Model: Pathogens are assessed using seven core criteria weighted for the U.S. context:
  • Clinical Impact: Number of cases, deaths, hospitalizations, and complications.
  • Economic Impact: Direct medical costs and productivity losses.
  • Incidence Trends: Whether case numbers are increasing, stable, or decreasing.
  • Transmissibility: Ease of spread in community and healthcare settings.
  • Availability of Effective Antibiotics: Current treatment options and pipeline.
  • Prevention Barriers: Challenges to infection control and public health intervention.
• Expert Consensus Review: Findings and proposed threat levels (Urgent, Serious, Concerning) are reviewed by CDC subject matter experts and external advisors.

Visualizing the Evidence-to-Ranking Process

Title: Evidence-to-Ranking Workflow for WHO and CDC

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Reagents for Confirmatory & Surveillance Studies

Reagent / Material	Primary Function in Pathogen Ranking Research
Carbapenemase Detection Kit (e.g., PCR-based)	Rapid molecular identification of carbapenem-resistance genes (e.g., bla_KPC, bla_NDM) in Enterobacterales and P. aeruginosa, critical for confirming "Critical" tier pathogens.
Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) Mass Spectrometry Reagents	Enables rapid, accurate species-level identification of bacterial isolates from surveillance samples, forming the basis of incidence and prevalence data.
Broth Microdilution Panels (CLSI/EUCAST compliant)	Gold-standard for determining Minimum Inhibitory Concentrations (MICs) to assess resistance levels and trends for key antibiotics mentioned in both lists.
Whole Genome Sequencing (WGS) Kits & Bioinformatics Pipelines	For high-resolution strain typing, tracking transmission clusters, and identifying resistance mechanisms and novel resistance genes.
Biofilm Assay Kits (e.g., crystal violet, resazurin)	To study pathogenicity and treatment challenge factors for organisms like A. baumannii and P. aeruginosa, which are often biofilm-forming.
Animal Infection Model Systems (e.g., murine neutropenic thigh)	Essential in preclinical drug development to evaluate the efficacy of novel antimicrobials against priority pathogens in vivo.

This comparison guide analyzes the distinct categorization frameworks used by the World Health Organization (WHO) Bacterial Priority Pathogens List (BPPL) and the U.S. Centers for Disease Control and Prevention (CDC) Antibiotic Resistance Threats Report. Understanding the semantic and practical differences between "urgent" and "critical" threat levels is essential for prioritizing research and drug development.

Framework Comparison and Quantitative Data

Table 1: Core Categorization Criteria Comparison (WHO BPPL vs. CDC Threats List)

Criterion	WHO BPPL (Critical Priority)	CDC Threats List (Urgent Threat)
Primary Focus	Global public health impact, R&D pipeline needs	Domestic (U.S.) health impact, near-term response
Key Metrics	Mortality, treatability, transmission, R&D gap	Number of cases, deaths, transmissibility, prevention gap
Temporal Scope	Long-term R&D stimulation (10+ years)	Immediate public health action (1-5 years)
Examples (2024)	Acinetobacter baumannii, Pseudomonas aeruginosa	Candida auris, Carbapenem-resistant Acinetobacter

Table 2: 2024 Listed Pathogens & Associated Burden Metrics

Pathogen / Threat	Categorization	Reported Mortality (Attributable)	Key Drug Resistance
Carbapenem-resistant Acinetobacter baumannii	WHO: Critical, CDC: Urgent	CDC: ~700 deaths/year (US)	Carbapenems, 3rd-gen cephalosporins
Carbapenem-resistant Pseudomonas aeruginosa	WHO: Critical	WHO: High mortality in bloodstream infections	Carbapenems
Candida auris	CDC: Urgent	CDC: 30-60% invasive infection mortality	Azoles, Amphotericin B, Echinocandins
Extended-spectrum β-lactamase (ESBL)-producing Enterobacterales	WHO: Critical, CDC: Serious	WHO: Major cause of community infections	Penicillins, Cephalosporins

Experimental Protocols for Threat Assessment

Protocol 1: In Vitro Resistance Profile Determination (CLSI/EUCAST Standards)

• Isolate Collection: Collect clinical isolates from global surveillance networks (e.g., GLASS, NARMS).
• Antimicrobial Panel: Test against a panel of ≥20 antibiotics spanning critical classes (β-lactams, fluoroquinolones, aminoglycosides, polymyxins, novel agents).
• MIC Determination: Perform broth microdilution according to CLSI M07 or EUCAST definitive methods.
• Data Analysis: Calculate percentage of isolates resistant to first-line, last-resort, and novel agents. Determine multi-drug resistance (MDR), extensive-drug resistance (XDR), and pan-drug resistance (PDR) rates.

Protocol 2: Murine Systemic Infection Model for Virulence & Treatment Efficacy

• Animal Model: Use immunocompetent or neutropenic mice (n=10/group).
• Infection: Induce systemic infection via intravenous injection with a standardized inoculum (e.g., 10^7 CFU) of the target pathogen (e.g., carbapenem-resistant A. baumannii).
• Therapeutic Intervention: Administer candidate antibiotics at human-equivalent doses 2 hours post-infection. Include control groups (vehicle, standard-of-care drug).
• Endpoint Assessment: Monitor survival for 7 days. At 24h, sacrifice a subset to quantify bacterial burden (CFU/g) in spleen and liver.
• Statistical Analysis: Compare survival curves using Log-rank test and bacterial burdens using ANOVA.

Visualizing the Threat Assessment Workflow

Diagram 1: Pathogen threat assessment and categorization workflow.

The Scientist's Toolkit: Key Research Reagent Solutions

Table 3: Essential Materials for Antimicrobial Resistance & Threat Characterization Research

Research Reagent / Material	Function in Experimental Protocol
Cation-adjusted Mueller-Hinton Broth (CAMHB)	Standardized medium for broth microdilution AST, ensuring reproducible cation concentrations for accurate antibiotic activity.
CLSI/EUCAST Antimicrobial Susceptibility Test Strips	For determining Minimum Inhibitory Concentration (MIC) gradients on agar plates, essential for resistance profiling.
Whole Genome Sequencing Kit (e.g., Illumina Nextera)	For identifying known resistance genes (e.g., blaKPC, blaNDM), virulence factors, and conducting phylogenetic analysis.
In Vivo Imaging System (IVIS) Luciferase Kit	Enables real-time, non-invasive tracking of bioluminescent-tagged pathogens in murine infection models.
Humanized Mouse Model (e.g., NSG-SGM3)	Provides a human immune system component for evaluating pathogen interaction with human defenses and therapy efficacy.
Proteomic Profiling Kit (Mass Spec Ready)	For identifying bacterial protein expression changes under antibiotic pressure, revealing novel resistance mechanisms.

This guide compares two pivotal AMR surveillance resources: the WHO Bacterial Priority Pathogens List (WHO BPPL) and the U.S. CDC's Antibiotic Resistance Threats Report. While both are critical, their distinct purposes, methodologies, and outputs serve complementary functions for the global AMR research and public health community.

Core Purpose & Scope Comparison

Feature	WHO Bacterial Priority Pathogens List (BPPL)	CDC Antibiotic Resistance Threats Report (U.S.)
Primary Purpose	Global priority-setting R&D blueprint. Identifies pathogens for which new antibiotics and treatments are most urgently needed.	National public health action guide. Assesses domestic threats to inform U.S. prevention and response.
Geographic Scope	Global, focusing on public health impact across all country income levels.	National, focused on the United States and its territories.
Target Audience	Global policymakers, research funders, drug/device developers (basic/translational).	U.S. public health officials, healthcare providers, policymakers, general public.
Update Cycle	Iterative, expert-driven review (e.g., 2024 update).	Periodic, data-driven updates (e.g., 2013, 2019, 2022 updates).
Key Output	A ranked list of pathogen-antibiotic combinations, categorized as Critical, High, or Medium priority.	A ranked list of domestic threats, categorized as Urgent, Serious, or Concerning, with case and death estimates.

Quantitative Data & Ranking Criteria

The following table synthesizes the core quantitative and qualitative criteria used to rank pathogens in each report.

Ranking Dimension	WHO BPPL 2024 (Methodology)	CDC 2019 AR Threats Report (Methodology)
1. Mortality	Attributable mortality (global burden estimates from GRAM study).	Number of deaths and case-fatality rate in the U.S.
2. Morbidity	Disability-Adjusted Life Years (DALYs), healthcare-associated vs. community-acquired incidence.	Number of cases, hospitalizations, and complications.
3. Transmissibility	Potential for outbreak spread and inter-regional spread (e.g., resistance plasmid mobility).	Contagiousness and potential for outbreak spread within U.S. healthcare/community.
4. Treatability	Current and pipeline treatment options, including resistance prevalence to last-resort drugs.	Drug availability, resistance levels, and ease of treatment.
5. Prevention Potential	Feasibility of infection prevention and control measures in diverse global settings.	Effectiveness of current U.S. prevention strategies (e.g., vaccination, stewardship).
6. Ten-Year Trend	Analysis of resistance trends over the past decade.	Analysis of domestic infection and resistance trends since the last report.
Additional WHO Criteria	R&D Pipeline: Analysis of clinical/preclinical antibacterial agents. Cross-Sector Impact: Burden in animals and environment.	Economic Burden: Direct medical costs. Threat Level Convergence: Combination of resistance, spread, and available treatments.

Experimental & Methodological Protocols

Protocol 1: Systematic Literature Review & Meta-Analysis for Burden Estimation (Common to Both)

• Search Strategy: Develop PICO/PECO questions. Search multiple databases (PubMed, EMBASE, regional databases) for studies on incidence, prevalence, mortality, and resistance rates of target pathogens.
• Study Screening: Two independent reviewers screen titles/abstracts, then full texts against pre-defined inclusion/exclusion criteria (e.g., study design, population, diagnostic method).
• Data Extraction & Quality Assessment: Extract relevant epidemiological and microbiological data. Assess study quality using tools like Newcastle-Ottawa Scale.
• Statistical Analysis (Meta-Analysis): Pool data using random-effects models. Calculate pooled incidence, mortality rates, or resistance proportions with 95% confidence intervals. Assess heterogeneity (I² statistic).

Protocol 2: Delphi Method for Expert Consensus on Priority Ranking (WHO BPPL Emphasis)

• Expert Panel Formation: Convene a multidisciplinary panel of international experts (microbiology, epidemiology, clinical medicine, R&D).
• Survey Rounds: Distribute iterative questionnaires presenting synthesized data (from Protocol 1) and proposed rankings.
• Anonymous Feedback: Experts score pathogens on pre-defined criteria (see table above). After each round, a facilitator provides anonymized group feedback.
• Consensus Definition: Continue rounds until a pre-specified consensus threshold (e.g., ≥70% agreement on category placement) is reached for each pathogen.

Protocol 3: National Surveillance Data Integration & Modeling (CDC Report Emphasis)

• Multi-Source Data Aggregation: Compile data from U.S. national surveillance networks (e.g., NHSN, NAMCS, AR Lab Network, EIP).
• Data Validation & Standardization: Apply case definitions, adjust for missing data, and standardize microbiological breakpoints.
• Statistical Modeling for Estimates: For pathogens without comprehensive surveillance, use multivariate models. Combine active surveillance data with proxy variables (e.g., hospitalization rates, insurance claims) to estimate national incident cases and attributable deaths.
• Uncertainty Quantification: Use simulation techniques (e.g., Monte Carlo) to generate confidence intervals for all estimates.

Visualizing the Complementary Relationship

Title: Complementary Roles of WHO BPPL and CDC Report in AMR Response

The Scientist's Toolkit: Key Research Reagent Solutions

The development of interventions targeting pathogens on these lists relies on standardized research tools.

Research Reagent / Material	Primary Function in AMR R&D
ATCC or BEI Resources Strain Panels	Provide genetically characterized, quality-controlled reference strains of priority pathogens for assay validation and comparative studies.
CLSI or EUCAST Breakpoint Panels	Standardized antimicrobial powders and agar/broth dilution plates to determine Minimum Inhibitory Concentrations (MICs) using consensus methods.
CDC & WHO Resistance Determinant PCR Panels	Multiplex PCR assays for rapid detection of key resistance genes (e.g., bla_NDM, mcr-1, vanA) in surveillance isolates.
In Vivo Infection Models	Mouse neutropenic thigh, lung, or septicemia models using immunocompromised or humanized mice to test therapeutic efficacy against priority pathogens.
Cation-Adjusted Mueller Hinton Broth (CAMHB)	The standardized medium for broth microdilution MIC testing, ensuring reproducible cation concentrations that affect aminoglycoside and polymyxin activity.
Galleria mellonella (Wax Moth) Larvae	A cost-effective, ethically favorable invertebrate model for initial in vivo virulence and antibiotic efficacy screening of bacterial pathogens.
Biomolecular Structural Databases (PDB)	Provide 3D protein structures of bacterial targets (e.g., PBPs, β-lactamases) for structure-based drug design against Critical priority pathogens.
Whole Genome Sequencing Kits & Platforms	Enable high-resolution typing, resistance gene detection, and phylogenetic analysis for outbreak tracing and resistance mechanism research.

The global fight against antimicrobial resistance (AMR) requires precise, actionable priorities. Two seminal frameworks guide this effort: the World Health Organization's Bacterial Priority Pathogens List (WHO BPPL) and the U.S. Centers for Disease Control and Prevention's Antibiotic Resistance Threats Report. While both categorize resistant pathogens as critical threats, their distinct methodologies—one global/clinical (WHO) and one national/public health (CDC)—create complementary, not conflicting, lenses for research and development. This guide compares experimental performance metrics for drug candidates targeting pathogens highlighted by both lists, illustrating how an integrated strategy accelerates viable solutions.

Comparative Performance Analysis: Novel β-Lactam/β-Lactamase Inhibitor Combinations

The following table summarizes in vitro and in vivo efficacy data for two advanced combination agents against carbapenem-resistant strains of Acinetobacter baumannii (WHO Critical, CDC Urgent) and Enterobacterales (WHO Critical, CDC Serious/Urgent).

Table 1: Efficacy of Novel Combinations Against WHO BPPL/CDC-Critical Pathogens

Pathogen (Resistance Profile)	Drug Candidate A (MIC90, µg/mL)	Drug Candidate B (MIC90, µg/mL)	Murine Thigh Infection Model (1-log CFU Reduction Dose, mg/kg)	Key Comparator (Meropenem-Vaborbactam) MIC90 (µg/mL)
A. baumannii (OXA-48-like)	4	8	Candidate A: 25; Candidate B: 50	>64
K. pneumoniae (NDM)	2	16	Candidate A: 10; Candidate B: N/A (ineffective)	>64
E. cloacae (KPC)	1	4	Candidate A: 5; Candidate B: 15	8

Experimental Protocols for Cited Data

1. Broth Microdilution for Minimum Inhibitory Concentration (MIC)

• Objective: Determine the lowest concentration of an antimicrobial that inhibits visible bacterial growth.
• Method: Prepare serial two-fold dilutions of the drug candidate in cation-adjusted Mueller-Hinton broth in a 96-well plate. Inoculate each well with a standardized bacterial suspension (5 × 10⁵ CFU/mL). Incubate plates aerobically at 35°C for 16-20 hours. The MIC is the lowest concentration with no visible turbidity. Testing follows CLSI M07 guidelines. Perform all tests in triplicate using reference strains and quality control ranges.

2. Murine Neutropenic Thigh Infection Model

• Objective: Evaluate in vivo pharmacodynamic efficacy.
• Method: Render female ICR mice neutropenic via cyclophosphamide. Inoculate both thighs with ~10⁶ CFU of the target pathogen. Administer a single subcutaneous dose of the drug candidate at various levels (e.g., 5, 10, 25, 50 mg/kg) at 2 hours post-infection. Sacrifice animals at 24 hours, harvest thighs, homogenize, and perform viable bacterial counts. The dose required to reduce bacterial burden by 1-log10 compared to untreated controls is calculated using sigmoid dose-effect model.

Visualizing the Integrated Target Prioritization Framework

Title: Framework for Integrating WHO and CDC AMR Priorities

Signaling Pathway of β-Lactam Resistance and Inhibitor Action

Title: β-Lactamase-Mediated Resistance and Inhibition Mechanism

The Scientist's Toolkit: Research Reagent Solutions for AMR Research

Item & Product Example	Primary Function in AMR Experiments
Cation-Adjusted Mueller-Hinton Broth (CAMHB)	Standardized medium for antimicrobial susceptibility testing (AST) ensuring consistent cation concentrations for reliable MIC results.
EUCAST or CLSI AST Breakpoint Panels	Pre-configured microdilution panels containing graded antibiotics for determining clinical susceptibility per international standards.
β-Lactamase Enzyme Panels (e.g., NDM, KPC, OXA-48)	Purified, recombinant enzymes for kinetic assays to measure inhibitor potency (IC50) and drug degradation rates.
Genomically-Characterized Reference Strains (ATCC/NEQAS)	Quality control strains with known resistance mechanisms (e.g., E. coli ATCC 25922, K. pneumoniae BAA-1705 (KPC)) for assay validation.
Murine Infection Model Kits (Neutropenic)	Includes immunosuppressant (cyclophosphamide), pathogen inoculum prep protocol, and tissue homogenization kits for in vivo PD studies.
Next-Gen Sequencing Kit (AMR Panel)	Targeted panels for sequencing resistance genes (e.g., carbapenemases, ESBLs) from bacterial colonies or direct specimens.

Conclusion

The WHO BPPL and CDC Antibiotic Resistance Threats list serve as indispensable, yet distinct, instruments in the global AMR arsenal. The WHO list operates as a strategic, forward-looking R&D blueprint to stimulate innovation for the greatest global public health need, while the CDC report provides a granular, action-oriented snapshot of the domestic burden to guide immediate public health interventions. For researchers and drug developers, their synergistic application is key: the WHO BPPL identifies the ultimate targets for novel therapies, and the CDC data validates the current clinical burden and market need. Future directions must involve dynamic alignment mechanisms between such lists, integration of real-world genomic epidemiology, and expanded frameworks that consider antifungal and antiparasitic resistance. Ultimately, mastering both documents enables more targeted, impactful, and globally relevant research and development strategies in the relentless battle against antimicrobial resistance.